4CMenB was approved by the Food and Drug Administration (FDA) in the United States in January
2015 for people aged 10 through 25 years of age. 4CMenB should be used during pregnancy only
if clearly needed and sometimes, inadvertent exposure during pregnancy may also occur -
before the woman knows she is pregnant, for example. The objective of this study is to
evaluate the safety of 4CMenB during pregnancy and to help us learn more about the health of
women who have been vaccinated with 4CMenB within 30 days prior to their last menstrual
period (LMP) or at any time during pregnancy, and the health of their infants. Pregnant women
within the US who received at least 1 dose 4CMenB vaccine within 30 days prior to their last
menstrual period or at any time during pregnancy are eligible to participate. A woman may
self-enroll in the registry by calling the pregnancy registry telephone number directly or
their healthcare provider (HCP) can, with their consent, enroll them on their behalf.
Alternatively HCPs may report anonymous data on pregnancy exposures and outcomes occurring
within their network/health maintenance organization (HMO). The health of the woman and her
infant will be followed up until the end of the pregnancy.